ADVENTRX Pharmaceuticals to Host Conference Call and Webcast Discussion of First Quarter 2007 Results on May 7, 2007
April 30 2007 - 7:00AM
PR Newswire (US)
SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX) announced today that it intends to
report the Company's first quarter 2007 financial results via press
release after the financial markets close on Monday, May 7, 2007.
Following the announcement, Evan M. Levine, Chief Executive Officer
and Gregory P. Hanson, Senior Vice President and Chief Financial
Officer are scheduled to host a conference call and webcast
discussion of the results and provide a general corporate update.
Other members of ADVENTRX's executive management team will also be
available to take investor questions. Access to the event can be
obtained as follows: Live access on Monday, May 7, 2007, 1:30 p.m.
Pacific Time / 4:30 p.m. Eastern Time: - Telephone (877) 502-9274
(domestic) or (913) 981-5584 (international) - The webcast will be
available live by accessing ADVENTRX's website at
http://www.adventrx.com/ under "Investors" Replay access: -
Telephone replay will be available through June 7, 2007 by dialing
888-203-1112 and entering the passcode 4320902 - Replays of the
webcast will be available by accessing ADVENTRX's website at
http://www.adventrx.com/ under "Investors" for 30 days About
ADVENTRX Pharmaceuticals ADVENTRX Pharmaceuticals is a
biopharmaceutical research and development company focused on
commercializing proprietary product candidates for the treatment of
cancer and infectious diseases. The Company seeks to improve the
performance and safety of existing treatments by addressing
significant problems, such as drug metabolism and bioavailability,
excessive toxicity and treatment resistance. The Company's lead
product candidate, ANX-510 (CoFactor), is in Phase 3 and Phase 2b
clinical trials for the treatment of metastatic colorectal cancer,
as well as in a Phase 2 clinical trial for the treatment of
advanced breast cancer. More information can be found on ADVENTRX's
web site at http://www.adventrx.com/. Forward Looking Statement
ADVENTRX cautions you that statements included in this press
release that are not a description of historical facts are
forward-looking statements that involve risks and assumptions that,
if they materialize or do not prove to be accurate, could cause
ADVENTRX's results to differ materially from historical results or
those expressed or implied by such forward-looking statements.
These potential risks and uncertainties include, but are not
limited to: the risk that ADVENTRX will be unable to raise
sufficient capital to fund the projects necessary to meet its
anticipated or stated goals and milestones; the potential to
attract a strategic partner and the terms of any related
transaction; the ability to timely enroll subjects in ADVENTRX's
current and anticipated clinical trials; the potential for CoFactor
and ADVENTRX's other product candidates to receive regulatory
approval for one or more indications on a timely basis or at all,
and the uncertain process of seeking regulatory approval; other
difficulties or delays in developing, testing, manufacturing and
marketing of and obtaining regulatory approval for CoFactor or
ADVENTRX's other product candidates; the potential for regulatory
authorities to require additional preclinical work or other
clinical requirements to support regulatory filings; the scope and
validity of patent protection for CoFactor and ADVENTRX's other
product candidates; and other risks and uncertainties more fully
described in ADVENTRX's press releases and periodic filings with
the Securities and Exchange Commission. ADVENTRX's public filings
with the Securities and Exchange Commission are available at
http://www.sec.gov/. ADVENTRX assumes no obligation to revise or
update any forward-looking statement, including as set forth in
this press release, to reflect events or circumstances arising
after the date on which it was made. DATASOURCE: ADVENTRX
Pharmaceuticals, Inc. CONTACT: Investors: Ioana C. Hone for
ADVENTRX Pharmaceuticals, Inc., +1-858-552-0866; Media: Edie DeVine
of WeissComm Partners, +1-415-946-1081 Web site:
http://www.adventrx.com/ Company News On-Call:
http://www.prnewswire.com/gh/cnoc/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024